Therapeutic microRNAs in polycystic kidney disease

Matanel Yheskel, Vishal Patel

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Purpose of review microRNAs (miRNAs) are short noncoding RNAs that function as sequence-specific inhibitors of gene expression. Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of end-stage kidney failure with limited treatment options. The realization that miRNA upregulation, and thus its gain-of-function, can drive the progression of ADPKD has raised the possibility that anti-miRs represent a novel drug class for this disorder. Recent findings A common set of miRNAs are aberrantly expressed in various murine models of polycystic kidney disease. In particular two miRNAs, miR-17 family and miR-21, are both upregulated in kidney cysts and promote ADPKD progression in mouse models. miR-17 rewires cyst epithelial metabolism to enhance cyst proliferation. On the other hand, miR-21 represses proapoptotic genes and thus inhibits cyst apoptosis. Importantly, an anti-miR-17 drug has advanced through preclinical ADPKD studies, whereas an anti-miR-21 drug has already cleared phase I clinical trial. Summary miRNAs have emerged as new regulators of ADPKD pathogenesis. Anti-miRs represent a feasible and an entirely new class of drugs for the treatment of ADPKD.

Original languageEnglish (US)
Pages (from-to)282-289
Number of pages8
JournalCurrent Opinion in Nephrology and Hypertension
Volume26
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Autosomal Dominant Polycystic Kidney
Polycystic Kidney Diseases
MicroRNAs
Cysts
Pharmaceutical Preparations
Therapeutics
Small Untranslated RNA
Clinical Trials, Phase I
Renal Insufficiency
Disease Progression
Up-Regulation
Apoptosis
Kidney
Gene Expression
Genes

Keywords

  • anti-miRs
  • microRNAs
  • miR-17
  • miR-21
  • polycystic kidney disease

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Cite this

Therapeutic microRNAs in polycystic kidney disease. / Yheskel, Matanel; Patel, Vishal.

In: Current Opinion in Nephrology and Hypertension, Vol. 26, No. 4, 01.07.2017, p. 282-289.

Research output: Contribution to journalReview article

@article{eeaa3c589bd6453eaddbc43a8d7afab5,
title = "Therapeutic microRNAs in polycystic kidney disease",
abstract = "Purpose of review microRNAs (miRNAs) are short noncoding RNAs that function as sequence-specific inhibitors of gene expression. Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of end-stage kidney failure with limited treatment options. The realization that miRNA upregulation, and thus its gain-of-function, can drive the progression of ADPKD has raised the possibility that anti-miRs represent a novel drug class for this disorder. Recent findings A common set of miRNAs are aberrantly expressed in various murine models of polycystic kidney disease. In particular two miRNAs, miR-17 family and miR-21, are both upregulated in kidney cysts and promote ADPKD progression in mouse models. miR-17 rewires cyst epithelial metabolism to enhance cyst proliferation. On the other hand, miR-21 represses proapoptotic genes and thus inhibits cyst apoptosis. Importantly, an anti-miR-17 drug has advanced through preclinical ADPKD studies, whereas an anti-miR-21 drug has already cleared phase I clinical trial. Summary miRNAs have emerged as new regulators of ADPKD pathogenesis. Anti-miRs represent a feasible and an entirely new class of drugs for the treatment of ADPKD.",
keywords = "anti-miRs, microRNAs, miR-17, miR-21, polycystic kidney disease",
author = "Matanel Yheskel and Vishal Patel",
year = "2017",
month = "7",
day = "1",
doi = "10.1097/MNH.0000000000000333",
language = "English (US)",
volume = "26",
pages = "282--289",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Therapeutic microRNAs in polycystic kidney disease

AU - Yheskel, Matanel

AU - Patel, Vishal

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose of review microRNAs (miRNAs) are short noncoding RNAs that function as sequence-specific inhibitors of gene expression. Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of end-stage kidney failure with limited treatment options. The realization that miRNA upregulation, and thus its gain-of-function, can drive the progression of ADPKD has raised the possibility that anti-miRs represent a novel drug class for this disorder. Recent findings A common set of miRNAs are aberrantly expressed in various murine models of polycystic kidney disease. In particular two miRNAs, miR-17 family and miR-21, are both upregulated in kidney cysts and promote ADPKD progression in mouse models. miR-17 rewires cyst epithelial metabolism to enhance cyst proliferation. On the other hand, miR-21 represses proapoptotic genes and thus inhibits cyst apoptosis. Importantly, an anti-miR-17 drug has advanced through preclinical ADPKD studies, whereas an anti-miR-21 drug has already cleared phase I clinical trial. Summary miRNAs have emerged as new regulators of ADPKD pathogenesis. Anti-miRs represent a feasible and an entirely new class of drugs for the treatment of ADPKD.

AB - Purpose of review microRNAs (miRNAs) are short noncoding RNAs that function as sequence-specific inhibitors of gene expression. Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of end-stage kidney failure with limited treatment options. The realization that miRNA upregulation, and thus its gain-of-function, can drive the progression of ADPKD has raised the possibility that anti-miRs represent a novel drug class for this disorder. Recent findings A common set of miRNAs are aberrantly expressed in various murine models of polycystic kidney disease. In particular two miRNAs, miR-17 family and miR-21, are both upregulated in kidney cysts and promote ADPKD progression in mouse models. miR-17 rewires cyst epithelial metabolism to enhance cyst proliferation. On the other hand, miR-21 represses proapoptotic genes and thus inhibits cyst apoptosis. Importantly, an anti-miR-17 drug has advanced through preclinical ADPKD studies, whereas an anti-miR-21 drug has already cleared phase I clinical trial. Summary miRNAs have emerged as new regulators of ADPKD pathogenesis. Anti-miRs represent a feasible and an entirely new class of drugs for the treatment of ADPKD.

KW - anti-miRs

KW - microRNAs

KW - miR-17

KW - miR-21

KW - polycystic kidney disease

UR - http://www.scopus.com/inward/record.url?scp=85017444795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017444795&partnerID=8YFLogxK

U2 - 10.1097/MNH.0000000000000333

DO - 10.1097/MNH.0000000000000333

M3 - Review article

C2 - 28399020

AN - SCOPUS:85017444795

VL - 26

SP - 282

EP - 289

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 4

ER -